Skip to Main Content

Paper Details

Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes.
Diabetes Care
12
2023
Author NameAffiliation
Sebastian SchneeweissDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School
Elisabetta PatornoDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School
  • 1 - 2

Datasets

Release 1.2